CNTF Gene Therapy Confers Lifelong Neuroprotection in a Mouse Model of Human Retinitis Pigmentosa
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The long-term outcome of neuroprotection as a therapeutic strategy for preventing cell death in neurodegenerative disorders remains unknown, primarily due to slow disease progression and the inherent difficulty of assessing neuronal survival in vivo. Employing a murine model of retinal disease, we demonstrate that ciliary neurotrophic factor (CNTF) confers life-long protection against photoreceptor degeneration. Repetitive retinal imaging allowed the survival of intrinsically fluorescent cone photoreceptors to be quantified in vivo. Imaging of the visual cortex and assessment of visually-evoked behavioral responses demonstrated that surviving cones retain function and signal correctly to the brain. The mechanisms underlying CNTF-mediated neuroprotection were explored through transcriptome analysis, revealing widespread upregulation of proteolysis inhibitors, which may prevent cellular/extracellular matrix degradation and complement activation in neurodegenerative diseases. These findings provide insights into potential novel therapeutic avenues for diseases such as retinitis pigmentosa and amyotrophic lateral sclerosis, for which CNTF has been evaluated unsuccessfully in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hartong, D. T., Berson, E. L., & Dryja, T. P. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69740-7 · Cited by 2,924
Weber, B. H. F., Vogt, G., Pruett, R. C., Stöhr, H., & Felbor, U. (1994) · Nature Genetics · doi:10.1038/ng1294-352 · Cited by 656
Retinopathy induced in mice by targeted disruption of the rhodopsin gene
Humphries, M. M., Rancourt, D., Farrar, G. J., Kenna, P., Hazel, M., Bush, R. A., Sieving, P. A., Sheils, D. M., Creighton, P., Erven, A., et al. (1997) · Nature Genetics · doi:10.1038/ng0297-216 · Cited by 529
Peterson, W. M., Wang, Q., Tzekova, R., & Wiegand, S. J. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04081.2000 · Cited by 267
Jacobson, S. G., Acland, G. M., Aguirre, G. D., Aleman, T. S., Schwartz, S. B., Cideciyan, A. V., Zeiss, C. J., Komaromy, A. M., Kaushal, S., Roman, A. J., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.005 · Cited by 224
Effect of CNTF on retinal ganglion cell survival in experimental glaucoma
Pease, M. E., Zack, D. J., Berlinicke, C., Bloom, K., Cone, F., Wang, Y., Klein, R. L., Hauswirth, W. W., & Quigley, H. A. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-3013 · Cited by 222
Chong, N. H. V., Keonin, J., Luthert, P. J., Frennesson, C. I., Weingeist, D. M., Wolf, R. L., Mullins, R. F., & Hageman, G. S. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62248-1 · Cited by 218
Kassen, S. C., Thummel, R., Campochiaro, L. A., Harding, M. J., Bennett, N. A., & Hyde, D. R. (2009) · Experimental Eye Research · doi:10.1016/j.exer.2009.01.007 · Cited by 116
Rhee, K. D., Nusinowitz, S., Chao, K., Yu, F., Bok, D., & Yang, X.-J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303604110 · Cited by 92
Cited by
Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer
Jones, S. A., & Jenkins, B. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0066-7 · Cited by 1,102
Dias, M. F., Joo, K., Kemp, J. A., Fialho, S. L., da Silva Cunha, A., Woo, S. J., & Kwon, Y. J. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.10.004 · Cited by 413
Principles of pharmacology in the eye
Awwad, S., Mohamed Ahmed, A. H. A., Sharma, G., Heng, J. S., Khaw, P. T., Brocchini, S., & Lockwood, A. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14024 · Cited by 224
“CNTF has been shown to be protective against ganglion cell death in models of oxidative stress and experimental glaucoma (Lipinski et al., 2015).”
Fischer, M. D., McClements, M. E., Martinez-Fernandez de la Camara, C., Bellingrath, J.-S., Dauletbekov, D., Ramsden, S. C., Hickey, D. G., Barnard, A. R., & MacLaren, R. E. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.005 · Cited by 112
“AAV2/8 batches were produced by transient co-transfection of HEK293T cells seeded in cell factories (HYPERflask; Corning), purified using iodixanol gradient ultracentrifugation, and concentrated by buffer exchange (Amicon Ultra-15; Millipore) to remove residual iodixanol as previously described.(29) Capsid proteins fo…”
MethodSelf-citationAdvances in gene therapy for diseases of the eye
Petit, L., Khanna, H., & Punzo, C. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.040 · Cited by 82
“A recent study in Rho mice showed that intraocular delivery of AAV2-hCNTF can confer long-term rod and cone photoreceptors protection and significantly delay vision loss even when rod death is well advanced.(130) However, the mode of action of CNTF is not fully understood, and even though CNTF is protective in animals…”
Background
Metadata
- Authors
- Lipinski, D. M., Barnard, A. R., Singh, M. S., Martin, C., Lee, E. J., Davies, W. I. L., & MacLaren, R. E.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 23
- Issue
- 8
- Pages
- 1308-1319
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2059500485
- Cited by
- 72
- References
- 9
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.